CGTX Cognition Therapeutics Inc.

FDA Catalyst Company
2.8
-0.06  -2%
Previous Close 2.86
Open 2.9
52 Week Low 2.31
52 Week High 13.8
Market Cap $63,274,140
Shares 22,597,907
Float 15,458,634
Enterprise Value $73,648,888
Volume 7,088
Av. Daily Volume 75,264
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Ladenburg Thalmann Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/22/2022
Oppenheimer Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/03/2021

Latest News

  1. PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the "Company" or "Cognition"), today announced that Lisa Ricciardi, the Company's president and CEO and Mary Hamby, Ph.D., vice president of research, will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.

    A live and archived webcast will be available on the H.C. Wainwright meeting platform and on the Investors section of the company's website at https://ir.cogrx.com. In addition, Ms. Ricciardi and Dr. Hamby will be available…

    View Full Article
  2. Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease

    Data Presented at Scientific Conferences Further Validate the Potential of σ-2 Modulators

    PURCHASE, N.Y., May 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today reported financial results for the first quarter ended March 31, 2022 and provided recent business updates.

    "Throughout the first quarter, we continued to drive the research and development of our lead…

    View Full Article
  3. PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the "Company" or "Cognition"), today announced that it will report financial results for the first quarter ended March 31, 2022 and provide a business update before the financial markets open on Tuesday, May 11, 2022.

    About Cognition Therapeutics, Inc.
    Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently…

    View Full Article
  4. NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina, presented a poster today at the annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) demonstrating that sigma-2 (σ-2) receptor modulators may restore the homeostatic functioning of retinal pigment epithelial (RPE) cells that is disrupted in dry age-related macular degeneration (dry AMD).

    Dry AMD is characterized by a progressive deterioration of the macula, a region of the retina comprised of photoreceptors and RPE cells, which support photoreceptors and are essential for the health…

    View Full Article
  5. NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting a poster at the annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) summarizing preclinical results showing that sigma-2 (σ-2) receptor modulators protect RPE cells and normalize key homeostatic processes disrupted in dry age-related macular degeneration (dry AMD). Cognition plans to initiate a Phase 2 clinical study for CT1812, the company's lead σ-2 receptor modulator, in patients with dry AMD.

    Oxidative stress and toxic proteins such as amyloid-beta (Aβ) oligomers…

    View Full Article
View All Cognition Therapeutics Inc. News